Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neurop

Recent advances in the management of diabetic distal symmetrical polyneuropathy

(2011) Solomon Tesfaye   Journal of Diabetes Investigation

Low Peripheral Nerve Conduction Velocities and Amplitudes Are Strongly Related to Diabetic Microvascular Complications in Type 1 Diabetes: The EURODIAB Prospective Complications Study

(2010) M. Charles et al.   DIABETES CARE

Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments

(2010) S. Tesfaye et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

(2010) et al.   Journal of Diabetes Investigation

Mechanism of diabetic neuropathy: Where are we now and where to go?

(2010) Soroku Yagihashi et al.   Journal of Diabetes Investigation

The Transforming Growth Factor-  Pathway Is a Common Target of Drugs That Prevent Experimental Diabetic Retinopathy

(2009) C. Gerhardinger et al.   DIABETES

Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review

(2009) Kate E. Schemmel et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy

(2009) Maria Nebuchennykh et al.   JOURNAL OF NEUROLOGY

Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy

(2008) Peter Oates   CURRENT DRUG TARGETS

Peripheral Sensory Neuropathy Associates With Micro- or Macroangiopathy: Results from a population-based study of type 2 diabetic patients in Sweden

(2008) L. Karvestedt et al.   DIABETES CARE

Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat

(2008) N Hotta et al.   DIABETIC MEDICINE